Literature DB >> 9421275

Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats.

K N Ting1, W R Dunn, D J Davies, D Sugden, P Delagrange, B Guardiola-Lemaître, E Scalbert, V G Wilson.   

Abstract

1. In this study we compared the vasoconstrictor activity of melatonin in rat isolated tail artery using two different recording systems, the Halpern pressure myograph and the Halpern-Mulvany wire myograph, with the view to determining a reliable method for obtaining pharmacological data on vascular melatonin receptors. In addition, we characterized the melatonin receptor in this preparation, using analogues of melatonin, and examined the activity of various naphthalenic derivatives with biological activity in non-vascular models of melatonin receptors. 2. Using the Halpern pressure myograph, cumulative addition of melatonin (0.1 nM to 1 microM) produced direct vasoconstriction (19.3+/-6.4% reduction in lumen diameter, n=5) in five of 11 pressurized segments, with pEC50 of 9.14+/-0.17. Similarly, non-cumulative application of melatonin caused vasoconstriction (19.7+/-4.6% reduction in lumen diameter, n=7) in seven of 20 preparations examined with pEC50 of 8.74+/-0.26. The selective alpha2-adrenoceptor agonist, UK-14304 (5-bromo-6-[2-imidazolin-2-ylamino]-quinoxaline bitartrate), produced vasoconstriction in all 'melatonin-insensitive' preparations. 3. Melatonin (0.1 nM to 1 microM) failed to elicit isometric contractions of tail artery segments in the Halpern wire myograph, but produced concentration-dependent potentiation of electrically-evoked, isometric contractions (maximum effect of 150-200% enhancement) when applied either noncumulatively (seven of seven preparations) or cumulatively (four of seven preparations). The pEC50 value of melatonin (non-cumulative) was 8.50+/-0.10 (n=7) which was not different from that obtained in the pressure myograph. All further experiments were conducted using a non-cumulative protocol against electrically-evoked, isometric contractions. 4. Based on the pEC50 values for the melatonin analogues examined, the pharmacological profile for the enhancement of electrically-evoked contractions was 2-iodomelatonin > 6-chloromelatonin > or = (-)-AMMTC > or = S21634 > or = melatonin > or = S20098 > S20242 > or = S20304 > 6-hydroxymelatonin > S20932 > (+)-AMMTC > N-acetyl-5-HT. Our data suggests the vascular receptor belongs to the MEL1-like subtype. All the indole-based analogues of melatonin, 2-iodomelatonin, (-)-AMMTC, (+)-AMMTC, S20932, 6-chloromelatonin, 6-hydroxymelatonin and N-acetyl-5-HT, behaved as full agonists. All the naphthalenic derivatives examined, S21634, S20098, S20242 and S20304 behaved as partial agonists relative to melatonin. 5. The naphthalenic-based antagonists, S20928 and S20929, did not modify electrically-evoked, isometric contractions of the tail artery, but produced a parallel, rightward displacement of the melatonin concentration-response curve. Based upon the effect of 1 microM S20928 and S20929, the estimated pK(B) values for these antagonists were 7.18+/-0.25 (n=4) and 7.17+/-0.25 (n=5), respectively. 6. We demonstrated that enhancement of electrically-evoked, isometric contractions of the rat isolated tail artery (using the Halpern-Mulvany wire myograph) is a simple and reproducible model for assessing the activity of putative agonists, partial agonists and antagonists at vascular melatonin receptors. Pharmacological characterization of the receptor suggests the presence of a MEL1-like subtype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421275      PMCID: PMC1565073          DOI: 10.1038/sj.bjp.0701511

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

Review 1.  Melatonin membrane receptors in peripheral tissues: distribution and functions.

Authors:  Radomir M Slominski; Russel J Reiter; Natalia Schlabritz-Loutsevitch; Rennolds S Ostrom; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

Review 2.  Hepatoprotective actions of melatonin: possible mediation by melatonin receptors.

Authors:  Alexander M Mathes
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

3.  Effects of melatonin on rat pial arteriolar diameter in vivo.

Authors:  O Régrigny; P Delagrange; E Scalbert; I Lartaud-Idjouadiene; J Atkinson; J M Chillon
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Molecular and pharmacological evidence for MT1 melatonin receptor subtype in the tail artery of juvenile Wistar rats.

Authors:  K N Ting; N A Blaylock; D Sugden; P Delagrange; E Scalbert; V G Wilson
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

6.  The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores.

Authors:  M T Teh; D Sugden
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

7.  Dose-dependent dual effect of melatonin on ototoxicity induced by amikacin in adult rats.

Authors:  Tamer Erdem; Orhan Ozturan; Mustafa Iraz; Murat Cem Miman; Ercument Olmez
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-05-28       Impact factor: 2.503

8.  New selective ligands of human cloned melatonin MT1 and MT2 receptors.

Authors:  Valérie Audinot; François Mailliet; Chantal Lahaye-Brasseur; Anne Bonnaud; Aude Le Gall; Christophe Amossé; Sandra Dromaint; Marianne Rodriguez; Nadine Nagel; Jean-Pierre Galizzi; Benoît Malpaux; Gérald Guillaumet; Daniel Lesieur; François Lefoulon; Pierre Renard; Philippe Delagrange; Jean A Boutin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-23       Impact factor: 3.000

9.  Noradrenaline can restore decreased neurogenic vasoreactivity.

Authors:  O V Karachentseva; V N Yartsev; D P Dvoretskii
Journal:  Neurosci Behav Physiol       Date:  2009-01-13

10.  Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries.

Authors:  Praveen Shukla; Chengwen Sun; Stephen T O'Rourke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-19       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.